Acadia Pharmaceuticals and CRISPR Therapeutics both trounced the market last year. Here's why that could continue.
News & Analysis: CRISPR Therapeutics
The gene-editing pioneer reported data from the first two patients dosed with its first drug candidate. The early results didn't disappoint.
Exponential growth is on the horizon for these companies. Investors should take note.
Find out which one of these gene-editing stocks makes a better portfolio addition right now.
Both of these gene editing stocks have a lot going for them, but which one is better?
Both of these gene-editing stocks are appealing, but which one reigns supreme?
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
More pipeline activity than ever before could usher in a big boom for CRISPR gene-editing stocks next year.
An early-stage start-up with an improved version of CRISPR gene editing filed to go public. Investors may want to keep an eye on it.
The rare-disease specialist is putting together a respectable end-of-year run.